M

Maat Pharma SA
PAR:MAAT

Watchlist Manager
Maat Pharma SA
PAR:MAAT
Watchlist
Price: 8 EUR -1.48% Market Closed
Market Cap: 111.4m EUR

Intrinsic Value

MAAT's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one MAAT stock under the Base Case scenario is 1.9 EUR. Compared to the current market price of 8 EUR, Maat Pharma SA is Overvalued by 76%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

MAAT Intrinsic Value
1.9 EUR
Overvaluation 76%
Intrinsic Value
Price
M
Worst Case
Base Case
Best Case

Valuation History
Maat Pharma SA

Intrinsic Value History
Dive into the past to invest in the future

Uncover deeper insights with the Valuation History. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start now and learn if your stock is truly undervalued or overvalued!

Start Valuation
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
How do you feel about MAAT?
Bearish
Neutral
Bullish

Fundamental Analysis

Maat Pharma SA
FR
Biotechnology
Market Cap
111.3m EUR
IPO
Nov 8, 2021
Employees
43
France
Market Cap
111.3m EUR
Industry
Biotechnology
IPO
Nov 8, 2021
Company Overview
Loading...
Management
Loading...
Contacts
Loading...
AI Assistant
AI Assistant
Ask me anything about Maat Pharma SA
Financials
Annual
Quarterly
TTM

Revenue & Expenses Breakdown
Maat Pharma SA

Balance Sheet Decomposition
Maat Pharma SA

Current Assets 40.6m
Cash & Short-Term Investments 32.1m
Receivables 7.1m
Other Current Assets 1.5m
Non-Current Assets 10.3m
Long-Term Investments 200k
PP&E 8.5m
Intangibles 1.3m
Other Non-Current Assets 238k
Efficiency

Earnings Waterfall
Maat Pharma SA

Revenue
2.6m EUR
Cost of Revenue
-826k EUR
Gross Profit
1.7m EUR
Operating Expenses
-25.9m EUR
Operating Income
-24.2m EUR
Other Expenses
27k EUR
Net Income
-24.1m EUR
Fundamental Scores

MAAT Profitability Score
Profitability Due Diligence

Maat Pharma SA's profitability score is 26/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional Revenue Growth Forecast
ROIC is Increasing
Positive 1-Year Revenue Growth
26/100
Profitability
Score

Maat Pharma SA's profitability score is 26/100. The higher the profitability score, the more profitable the company is.

MAAT Solvency Score
Solvency Due Diligence

Maat Pharma SA's solvency score is 46/100. The higher the solvency score, the more solvent the company is.

Negative Net Debt
Low D/E
Short-Term Solvency
Long-Term Solvency
46/100
Solvency
Score

Maat Pharma SA's solvency score is 46/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

MAAT Price Targets Summary
Maat Pharma SA

Wall Street analysts forecast MAAT stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MAAT is 16.49 EUR with a low forecast of 13.94 EUR and a high forecast of 22.05 EUR.

Lowest
Price Target
13.94 EUR
74% Upside
Average
Price Target
16.49 EUR
106% Upside
Highest
Price Target
22.05 EUR
176% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Maat Pharma SA
does not pay dividends
Shareholder Yield

Current shareholder yield for MAAT is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

MAAT Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one MAAT stock?

The intrinsic value of one MAAT stock under the Base Case scenario is 1.9 EUR.

Is MAAT stock undervalued or overvalued?

Compared to the current market price of 8 EUR, Maat Pharma SA is Overvalued by 76%.

Back to Top